Leerink Partnrs Issues Negative Estimate for CRNX Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for shares of Crinetics Pharmaceuticals in a report issued on Tuesday, February 4th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($1.14) for the quarter, down from their prior forecast of ($1.12). The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($3.73) per share. Leerink Partnrs also issued estimates for Crinetics Pharmaceuticals' Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.24) EPS and FY2026 earnings at ($4.99) EPS.

Other analysts have also issued research reports about the company. Jefferies Financial Group raised Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 target price for the company in a report on Wednesday, January 22nd. Citigroup raised their price target on Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a "buy" rating in a research note on Thursday, November 14th. HC Wainwright restated a "buy" rating and issued a $81.00 price target on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. JMP Securities restated a "market outperform" rating and issued a $87.00 price target on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. Finally, Wolfe Research initiated coverage on Crinetics Pharmaceuticals in a research report on Tuesday, February 4th. They set a "peer perform" rating on the stock. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Crinetics Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $72.64.

Crinetics Pharmaceuticals Price Performance

CRNX stock traded down $1.67 on Friday, reaching $34.86. 411,192 shares of the company traded hands, compared to its average volume of 1,028,203. The company has a market cap of $3.23 billion, a P/E ratio of -9.36 and a beta of 0.56. The firm has a fifty day simple moving average of $46.99 and a 200-day simple moving average of $51.62. Crinetics Pharmaceuticals has a one year low of $34.77 and a one year high of $62.53.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.05). During the same quarter in the prior year, the company earned ($1.01) earnings per share.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CRNX. SG Americas Securities LLC increased its stake in Crinetics Pharmaceuticals by 4,084.6% during the fourth quarter. SG Americas Securities LLC now owns 542,446 shares of the company's stock worth $27,735,000 after acquiring an additional 529,483 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Crinetics Pharmaceuticals by 61.4% during the third quarter. Franklin Resources Inc. now owns 1,390,110 shares of the company's stock worth $73,815,000 after buying an additional 528,688 shares during the period. FMR LLC lifted its holdings in Crinetics Pharmaceuticals by 8.8% during the third quarter. FMR LLC now owns 4,455,770 shares of the company's stock worth $227,690,000 after buying an additional 358,975 shares during the period. Vestal Point Capital LP purchased a new stake in Crinetics Pharmaceuticals during the third quarter worth $10,476,000. Finally, Geode Capital Management LLC increased its position in shares of Crinetics Pharmaceuticals by 10.1% during the third quarter. Geode Capital Management LLC now owns 1,848,133 shares of the company's stock worth $94,458,000 after purchasing an additional 169,746 shares in the last quarter. 98.51% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Jeff E. Knight sold 501 shares of Crinetics Pharmaceuticals stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $56.52, for a total value of $28,316.52. Following the sale, the chief operating officer now directly owns 51,653 shares of the company's stock, valued at approximately $2,919,427.56. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $39.07, for a total value of $195,350.00. Following the completion of the sale, the insider now directly owns 31,748 shares in the company, valued at $1,240,394.36. This trade represents a 13.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.00% of the company's stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.